Pharmacist urges law to modernize 340B discounts for multi-use orphan drugs

A pharmacist argues that current legislation lags behind the evolving use of orphan-designated medicines, many of which now serve multiple therapeutic indications.

The piece highlights the 340B drug discount program, noting that its rules were written before such multi-use scenarios became common, creating uncertainty for providers and manufacturers.

The author calls for legislative updates to clarify how orphan drug status and 340B pricing interact, aiming to ensure patients continue to receive affordable treatments while preserving incentives for drug development.